Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit, and GGZ InGeest, Amsterdam, the Netherlands.
Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, the Netherlands; Arkin Institute for Mental Health, Amsterdam, the Netherlands.
J Psychiatr Res. 2021 Mar;135:143-151. doi: 10.1016/j.jpsychires.2021.01.009. Epub 2021 Jan 16.
Depressive symptoms are highly prevalent and clinically relevant in schizophrenia spectrum disorder (SSD) patients. So far, little is known about to what extent the depressive symptom profile in SSD is comparable to that seen in major depressive disorder (MDD).
Data were derived from the Genetic Risk and Outcome of Psychosis study (GROUP) and the Netherlands Study of Depression and Anxiety (NESDA). We examined differences in severity of depressive symptom profiles and distribution of mood/cognition and somatic/vegetative depressive symptoms using the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR) within SSD patients (n = 449), MDD patients (n = 816) and healthy controls (n = 417), aged 18 to 50. Within SSD, associations between depression severity and clinical and demographic data were examined.
60.4% of SSD patients showed substantial depressive symptomatology (QIDS-SR≥6). The difference in mood/cognition symptoms between SSD and MDD was larger (higher symptoms in MDD, effect size = 1.13), than the differences in somatic/vegetative symptoms (effect size 0.74). In patients with SSD, multivariable regression analyses showed that lower social functioning, male gender, use of benzodiazepine and more severe positive symptoms were associated with higher overall depressive symptomatology. The use of antipsychotics or antidepressants was associated with more somatic/vegetative symptoms.
More than half of SSD patients have considerable depressive symptomatology, with a relative preponderance of somatic/vegetative symptoms compared to the profile seen in MDD. Future research could explore whether depressive symptom profile in SSD may also be associated with biological dysregulations like in MDD.
抑郁症状在精神分裂症谱系障碍(SSD)患者中普遍存在且具有临床相关性。迄今为止,对于 SSD 患者的抑郁症状谱在多大程度上与重性抑郁障碍(MDD)相似,我们知之甚少。
本研究数据来源于精神分裂症风险和结局研究(GROUP)和荷兰抑郁和焦虑研究(NESDA)。我们使用贝克抑郁自评量表(BDI)评估了 SSD 患者(n=449)、MDD 患者(n=816)和健康对照组(n=417)中抑郁症状严重程度和情绪/认知与躯体/植物性抑郁症状分布的差异,年龄为 18 至 50 岁。在 SSD 患者中,我们还评估了抑郁严重程度与临床和人口统计学数据之间的相关性。
60.4%的 SSD 患者存在明显的抑郁症状(BDI≥6)。与 MDD 相比,SSD 患者的情绪/认知症状差异更大(MDD 患者的症状更严重,效应量为 1.13),而躯体/植物性症状的差异较小(效应量为 0.74)。在 SSD 患者中,多变量回归分析显示,社会功能较差、男性、使用苯二氮䓬类药物和更严重的阳性症状与更高的总体抑郁症状相关。抗精神病药物或抗抑郁药物的使用与更多的躯体/植物性症状相关。
超过一半的 SSD 患者存在明显的抑郁症状,与 MDD 相比,躯体/植物性症状更为突出。未来的研究可以探讨 SSD 患者的抑郁症状谱是否也与 MDD 一样与生物学失调有关。